Developing non-opiate gpcr signaling-biased agents for pain management

This Project Grant award from the Defense Health Agency provides $1,606,737 to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the period of September 1, 2022 through August 31, 2026. The award supports the development of non-opiode GPCR signaling-biased agents for pain management by advancing a series of compounds represented by SBI-810 and SBI-553 toward an Investigational New Drug application. Under a subaward of $156,000, the University of Minnesota will provide assays characterizing and validating the biochemical and pharmacological activity of test compounds at the neurotensin 1 receptor, including studies necessary to generate a cryo-electron microscopy structure of SBI-553 and SBI-810. This work aims to eliminate or reduce the need for opioids in pain treatment through innovative medical research supported by the Defense Health Agency grant program.